Clues to Alzheimer’s disease may be hiding in our ‘junk’ DNA

(Press-News.org) When most of us think of DNA, we have a vague idea it’s made up of genes that give us our physical features, our behavioural quirks, and keep our cells and organs running.

But only a tiny percentage of our DNA – around 2% – contains our 20,000-odd genes. The remaining 98% – long known as the non-coding genome, or so-called ‘junk’ DNA – includes many of the switches that control when and how strongly genes are expressed.

Now researchers from UNSW Sydney have identified the DNA switches that help control how astrocytes work – these are brain cells that support neurons, and are known to play a role in Alzheimer’s disease.

In research published today in Nature Neuroscience, researchers from UNSW’s School of Biotechnology & Biomolecular Sciences described how they tested nearly 1000 potential switches – strings of DNA known as enhancers – in human astrocytes grown in the lab. Enhancers can be located very far away from the gene they control, sometimes hundreds of thousands of DNA letters away – making them difficult to study.

The team used CRISPRi, a tool that lets you turn off small sections of DNA without cutting it, combined with single-cell RNA sequencing, which measures gene expression in individual cells. This approach allowed them to test the function of nearly 1000 enhancers at once.

“We used CRISPRi to turn off potential enhancers in the astrocytes to see whether it changed gene expression,” says lead author Dr Nicole Green.

“And if it did, then we knew we’d found a functional enhancer and could then figure out which gene – or genes – it controls. That’s what happened for about 150 of the potential enhancers we tested. And strikingly, a large fraction of these functional enhancers controlled genes implicated in Alzheimer’s disease.”

Going from 1000 candidates to 150 real switches dramatically narrows where scientists need to look in the non-coding genome to find clues to the genetics of Alzheimer’s disease.

“These findings suggest that similar studies in other brain cell types are needed to highlight the functional enhancers in the vast space of non-coding DNA"

Reading between the lines

Professor Irina Voineagu, who oversaw the study, says the results give researchers a catalogue of DNA regions that can help interpret the results of other genetic studies as well.

“When researchers look for genetic changes that explain diseases like hypertension, diabetes and also psychiatric and neurodegenerative disorders like Alzheimer's disease – we often end up with changes not within genes so much, but in-between,” she says.

Those “in-between” regions are the enhancers her team has now tested directly in human astrocytes – revealing which ones genuinely control important brain genes.

“We’re not talking about therapies yet. But you can’t develop them unless you first understand the wiring diagram. That’s what this gives us — a deeper view into the circuitry of gene control in astrocytes.”

From gene switches to AI

Testing nearly a thousand enhancers in the lab was painstaking work. And it is the first time a CRISPRi screen of enhancers of this scale has been done in brain cells. But with the groundwork now done, the data can be used to train computer tools to predict which potential enhancers are true switches, potentially saving years of experimental time.

“This dataset can help computational biologists test how good their prediction models are at predicting enhancer function,” says Prof. Voineagu.

In fact, Google’s DeepMind team is already using the dataset to benchmark their recent deep learning model called AlphaGenome, she adds.

Potential tools for gene therapy

Because specific enhancers are only active in specific cell types, targeting them could allow precise control of gene expression in astrocytes without affecting neurons or other brain cells.

"While this is not close to being used in the clinic yet – and much work remains before these findings could lead to treatments – there is a clear precedent,” Prof. Voineagu says.

“The first gene editing drug approved for a blood disease – sickle cell anaemia – targets a cell-type specific enhancer.”

Dr Green adds that research into DNA enhancers is a promising direction in precision medicine.

“This is something we want to look at more deeply: finding out which enhancers we can use to turn genes on or off in a single brain cell type, and in a very controlled way,” she says.

END